Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Form 8.5 (EPT/RI) - NewRiver REIT Plc
-
Form 8.5 (EPT/RI) - Touchstone Exploration Inc.
-
Prepayments (CK93) - Totalkredit A/S
-
Prepayments (CK93) - Nykredit Realkredit A/S
-
Transactions in connection with share buyback programme
-
Baltic Horizon Fund closes private placement of new units
-
Alm. Brand A/S – Weekly report on share buybacks
-
Share buyback programme - week 37
-
Kronos Advanced Technologies, Inc. (OTC: KNOS) Announces Ex-Dividend Date for Upcoming Special Cash Dividend
-
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metas
-
Nokia and NL-ix deploy Deepfield for the largest IXP-based anti-DDoS protection for enterprises across Europe
-
Introducing THAT: Shifting from Cash to Innovation
-
Akur8 Secures $120 Million in Series C Round to Accelerate Growth of its Next Generation Actuarial Platform
-
Nexans awarded contract for first transmission link from Orkney Islands in Scotland
-
Form 8.5 (EPT/RI)-Eckoh Plc
-
Preliminary data on early redemptions (prepayments)
-
Aktsiaselts Infortar signed a share purchase agreement to acquire a 100% shareholding at Tallinna Raamatutrükikoja Osaühing
-
Syensqo announces voluntary delisting from Euronext Paris
-
SEB initiates coverage of Aktia and publishes initiation analysis
-
Share repurchase programme
-
Exor Press Release - Periodic Report on the Buyback Program
-
OKX Wallet and Uniswap Labs to Host 'Swap to the Future' Exhibition Event in Singapore
-
OKX Wallet and Uniswap Labs to Host 'Swap to the Future' Exhibition Event in Singapore
-
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
-
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B
-
Tonner Drones: Board and Management Changes Lead to Further Debt Reduction
-
Intermediate Capital Group plc : Directorate change
-
Net Asset Value(s)
-
Transaction in Own Shares
-
RIBER announces coverage initiation of its stock by TP ICAP Midcap
-
Sampo plc: Directed issuance of new Sampo A shares to Topdanmark shareholders in connection with the exchange offer
-
Sampo plc increases its share buyback programme to EUR 475 million and extends it until 30 November 2024
-
Sampo plc: Final result of the exchange offer to the shareholders of Topdanmark
-
Vallourec Enhances Its Line Pipe Coating Solutions With the Acquisition of Thermotite do Brasil
-
BGHL (EUR): NAV(s)
-
BGHL (GBP): NAV(s)
-
Sampo plc’s share buybacks 13 September 2024
-
Start of Day Message
-
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
-
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
-
Vera Bradley Foundation for Breast Cancer Raises $1,601,830 for Breast Cancer Research
-
Toden Announces Presale with 500X Potential: A New Community-Driven Meme Token
-
Rexel: Rexel Board of Directors rejects an unsolicited preliminary proposal from QXO
-
MEXC First to Launch CATI Spot and Futures trading. Share a Prize Pool of 1,000,000 CATI and 80,000 USDT in Futures Bonuses!
-
IMPERIAL PETROLEUM INC. Declares Dividend on Series A Preferred Shares
-
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
-
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
-
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
-
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
-
KFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care Solutions
